Chemerin-9 （149-157）

Research use only, not for human use.

The nonapeptide 149,YFPGQFAFS157 (chemerin-9), corresponding to the C terminus of processed chemerin, retained most of the activity of the full-size protein, with regard to agonism toward the chemerinR.the natural ligand of ChemR23 (chemerinR).

The nonapeptide 149,YFPGQFAFS157 (chemerin-9), corresponding to the C terminus of processed chemerin, retained most of the activity of the full-size protein, with regard to agonism toward the chemerinR.the natural ligand of ChemR23 (chemerinR).

Chemerin-9 (149-157) (0.1 nM; 24 h; cardiac fibroblasts) stimulates migration in cardiac fibroblasts and stimulates phosphorylation of Akt and ERK as well as ROS production. Western Blot Analysis Cell Line:Cardiac fibroblasts Concentration:0.1 nM Incubation Time:24 hours Result:Stimulated phosphorylation of Akt and ERK.

Chemerin-9 (149-157) (0.2 mg/kg; i.p.; daily, for 42 days) alleviates glucose intolerance and IR in PDM mice.Chemerin-9 (149-157) (7.7? μg /kg; i.h.; daily, for 28 days) has anti-inflammatory and anti-angiogenic effects in ApoE-/- mice and protects the abdominal aorta from MMP damage.Chemerin-9 (149-157) (8 μg/kg; ICV; daily; for 14 d; male Kunming mice) ameliorates Aβ1-42-induced memory impairment. Animal Model:PDM mice Dosage:0.2 mg/kg Administration:Intraperitoneal injection; daily, for 42 daysResult:Increased expression of chemerin, GLUT2, and PDX1, which led to the alleviation of glucose intolerance and IR in PDM model mice. Animal Model: ApoE-/- mice Dosage:7.7 μg /kg Administration:Subcutaneous injection; daily, for 28 days Result:Suppressed the enlargement of abdominal aorta and reversed the SMC loss.Animal Model:ApoE-/- mice Dosage:7.7 μg/kg Administration:Subcutaneous injection; daily, for 28 days Result:Down-regulated MMP2 and MMP-9 expression and decreased the levels of chemerin and CMKLR1.Animal Model:Male Kunming mice Dosage:8 μg/kg Administration:Intracerebroventrical injection; daily; for 14 days Result:Increased in the levels of pro-in?ammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor (TNF-α) and interleukin-6 (IL-6) in the hippocampus.

——

Membrane Transporter/Ion Channel

Beta Amyloid

——

——

——

676367-27-4

1063.16

C54H66N10O13

>98% (HPLC)

——

——

Sequence:{Tyr}{Phe}{Pro}{Gly}{Gln}{Phe}{Ala}{Phe}{Ser}

(-20℃)

With Ice Pack

≥ 2 years